vimarsana.com

ப்ரொஃபெஸர் ஆஃப் குழந்தை மருத்துவம் இல் மக்மாஸ்டர் பல்கலைக்கழகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Octapharma AG: Final data from the NuProtect study published on the immunogenicity of Nuwiq® in previously untreated patients with severe haemophilia A

Share this article Share this article LACHEN, Switzerland, Feb. 22, 2021 /PRNewswire/ Octapharma announced today that the final results from the NuProtect study on the immunogenicity of Nuwiq ® in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journal Thrombosis and Haemostasis (Liesner RJ et al. Simoctocog Alfa (Nuwiq ®) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0040-1722623). The NuProtect study (NCT01712438; EudraCT 2012-002554-23) was a prospective, multinational, open-label, non-controlled phase III study initiated in March 2013 to assess the immunogenicity, efficacy and safety of Nuwiq

United statesSwitzerland generalUnited kingdomCity ofNordrhein westfalenLarisa belyanskayaPrnewswire octapharmaAnthony chanOlaf walterProfessor of paediatrics at mcmaster universityPreviously untreated patientsSevere haemophiliaFinal resultsGreat ormond street hospitalBoard memberMcmaster university

Octapharma AG: Final data from the NuProtect study published on the [ ]

22 febbraio 2021 17:11 Fonte: Adnkronos #chimica-e-farmacia - LACHEN, Switzerland, Feb. 22, 2021 /PRNewswire/ Octapharma announced today that the final results from the NuProtect study on the immunogenicity of Nuwiq® in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journal Thrombosis and Haemostasis (Liesner RJ et al. Simoctocog Alfa (Nuwiq®) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0040-1722623). The NuProtect study (NCT01712438; EudraCT 2012-002554-23) was a prospective, multinational, open-label, non-controlled phase III study initiated in March 2013 to assess the immunogenicity, efficacy and safety of Nuwiq®. The study recruited patients of any age and ethnicity at 38 sites in 17 countries and followed patients for 100 exposure days or up to 5 years. With enrolment of 110 patients, th

United statesSwitzerland generalUnited kingdomCity ofNordrhein westfalenLarisa belyanskayaPrnewswire octapharmaAnthony chanOlaf walterProfessor of paediatrics at mcmaster universityPreviously untreated patientsSevere haemophiliaFinal resultsGreat ormond street hospitalBoard memberMcmaster university

Octapharma AG: Final data from the NuProtect study published on the immunogenicity of Nuwiq in previously untreated patients with severe haemophilia A

Octapharma AG: Final data from the NuProtect study published on the immunogenicity of Nuwiq in previously untreated patients with severe haemophilia A in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journal Thrombosis and Haemostasis (Liesner RJ et al. Simoctocog Alfa (Nuwiq ) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0040-1722623). The NuProtect study (NCT01712438; EudraCT 2012-002554-23) was a prospective, multinational, open-label, non-controlled phase III study initiated in March 2013 to assess the immunogenicity, efficacy and safety of Nuwiq

United statesUnited kingdomBaden wubergCity ofNordrhein westfalenKostenloser wertpapierhandelLarisa belyanskayaPrnewswire octapharmaAnthony chanOlaf walterProfessor of paediatrics at mcmaster universityPreviously untreated patientsSevere haemophiliaFinal resultsGreat ormond street hospitalBoard member

Final Data From the NuProtect Study Published on the Immunogenicity of Nuwiq® in Previously Untreated Patients With Severe Haemophilia A

Octapharma Final Data From the NuProtect Study Published on the Immunogenicity of Nuwiq® in Previously Untreated Patients With Severe Haemophilia A Thursday, February 18, 2021 4:01PM IST (10:31AM GMT) LACHEN, Switzerland: Octapharma announced today that the final results from the NuProtect study on the immunogenicity of Nuwiq ® in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journal Thrombosis and Haemostasis (Liesner RJ et al. “Simoctocog Alfa (Nuwiq ®) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study” https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0040-1722623). The NuProtect study (NCT01712438; EudraCT 2012-002554-23) was a prospective, multinational, open-label, non-controlled phase III study initiated in March 2013 to assess the immunogenicity, efficacy and saf

India generalUnited statesUnited kingdomCity ofNordrhein westfalenLarisa belyanskayaAnthony chanIvana spotakovaOlaf walterProfessor of paediatrics at mcmaster universityOctapharma ag international business unitPreviously untreated patientsSevere haemophiliaFinal resultsGreat ormond street hospitalBoard member

Octapharma: Final Data From the NuProtect Study Published on the Immunogenicity of Nuwiq in Previously Untreated Patients With Severe Haemophilia A

Octapharma: Final Data From the NuProtect Study Published on the Immunogenicity of Nuwiq in Previously Untreated Patients With Severe Haemophilia A in previously untreated patients (PUPs) with severe haemophilia A have been published in the leading medical journal Thrombosis and Haemostasis (Liesner RJ et al. Simoctocog Alfa (Nuwiq ) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0040-1722623). The NuProtect study (NCT01712438; EudraCT 2012-002554-23) was a prospective, multinational, open-label, non-controlled phase III study initiated in March 2013 to assess the immunogenicity, efficacy and safety of Nuwiq . The study recruited patients of any age and ethnicity at 38 sites in 17 countries and followed patients for 100 exposure days or up to 5 years. With enrolment of 110 patients, the NuProtect study was the largest clinical study to investigate a single

United statesSwitzerland generalUnited kingdomCity ofNordrhein westfalenKostenloser wertpapierhandelLarisa belyanskayaAnthony chanIvana spotakovaOlaf walterProfessor of paediatrics at mcmaster universityOctapharma ag international business unit haematologyPreviously untreated patientsSevere haemophiliaFinal resultsGreat ormond street hospital

vimarsana © 2020. All Rights Reserved.